Gilead Slumps After Cutting Earnings Outlook on Litigation Costs

  • 📰 markets
  • ⏱ Reading Time:
  • 16 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 59%

España Noticias Noticias

España Últimas Noticias,España Titulares

The company lowered its earnings outlook as a result of litigation costs accrued from settlements made to some plaintiffs in an antitrust lawsuit over its HIV drugs

shares erased a decline as a strong quarterly performance more than offset a lower profit outlook amid litigation costs. The stock rose as much as 1.2%.didn’t engage in an anticompetitive conspiracy

to delay generic versions of the HIV drugs. However, before the case went to trial, the companies reached a last-minute deal with major pharmacy chains and direct purchases. Gilead paid $525 million in settlements, according to a second-quarter earnings release, which shaved 32 cents off of per-share earnings.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 324. in ES
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Europe markets expected to open lower as investors digest earnings and U.S. rating downgradeEuropean markets are expected to open lower Wednesday as investors continue to digest earnings and the U.S. rating downgrade.
Fuente: CNBC - 🏆 12. / 72 Leer más »